Gain Therapeutics (GANX) awards director 25,000 stock options at $1.68
Rhea-AI Filing Summary
Gain Therapeutics, Inc. granted director GOLDSTEIN DOV A MD a stock option covering 25,000 shares of common stock at an exercise price of $1.68 per share. The option vests in 12 equal monthly installments beginning July 24, 2026, subject to his continuous service, and expires on July 15, 2036. Following this grant, he holds options on 25,000 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
GOLDSTEIN DOV A MD
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 25,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 25,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Stock options granted: 25,000 shares
Exercise price: $1.68 per share
Options held after grant: 25,000 shares
+2 more
5 metrics
Stock options granted
25,000 shares
Director stock option grant on July 15, 2026
Exercise price
$1.68 per share
Conversion or exercise price of the granted option
Options held after grant
25,000 shares
Total options following the reported transaction
Vesting schedule
12 monthly installments
Equal monthly vesting beginning July 24, 2026
Option expiration
July 15, 2036
Expiration date of the granted stock option
Key Terms
Stock Option (right to buy), exercise price, vests in 12 equal monthly installments, expiration date
4 terms
Stock Option (right to buy) financial
"Security title noted as Stock Option (right to buy)."
exercise price financial
"Conversion or exercise price reported as $1.6800 per share."
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vests in 12 equal monthly installments financial
"The option vests in 12 equal monthly installments commencing on July 24, 2026."
expiration date financial
"Option expiration date reported as 2036-07-15."
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What stock option grant did Gain Therapeutics (GANX) give to director Goldstein?
Gain Therapeutics granted director GOLDSTEIN DOV A MD a stock option for 25,000 shares of common stock at an exercise price of $1.68 per share. The grant represents his reported holdings of options on 25,000 shares after the transaction.
What is the exercise price of the new Gain Therapeutics (GANX) stock option?
The granted stock option has an exercise price of $1.68 per share. This allows the director to purchase up to 25,000 shares of Gain Therapeutics common stock at $1.68, regardless of the market price when the option is exercised before expiration.
How do the Gain Therapeutics (GANX) options granted to Goldstein vest?
The option vests in 12 equal monthly installments starting on July 24, 2026. Each month, one-twelfth of the 25,000-share grant becomes exercisable, provided the director continues in service through each applicable vesting date.
When do the newly granted Gain Therapeutics (GANX) stock options expire?
The stock option granted to the director expires on July 15, 2036. After this expiration date, any unexercised portion of the 25,000-share option will no longer be exercisable, even if it had previously vested under the vesting schedule.